UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2014 (January 21, 2014)
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-51820 | 77-0567768 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Alexza Pharmaceuticals, Inc. 2091 Stierlin Court | 94043 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 — Other Events
| Item 8.01. | Other Events. |
On January 21, 2014, Alexza Pharmaceuticals, Inc. (“Alexza” or the “Company”) announced that its commercial partner Grupo Ferrer Internacional, S.A. (“Ferrer”) has initiated sales of ADASUVE® inhalation powder, pre-dispensed (Staccato® Loxapine) in Spain. The commercial introduction of the product in Spain by Ferrer triggers a $1 million milestone payment to Alexza, pursuant to the Company’s collaboration agreement with Ferrer. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
Exhibit | Description | |
| 99.1 | Press Release titled “Alexza Pharmaceuticals Announces Grupo Ferrer’s Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment,” dated January 21, 2014. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALEXZA PHARMACEUTICALS, INC. | ||||||
| Date: January 21, 2014 | ||||||
| By: | /s/ Thomas B. King | |||||
Thomas B. King President and Chief Executive Officer | ||||||
INDEX TO EXHIBITS
Exhibit | Description | |
| 99.1 | Press Release titled “Alexza Pharmaceuticals Announces Grupo Ferrer’s Launch of ADASUVE® (Staccato® Loxapine) in Spain Triggering a $1 Million Milestone Payment,” dated January 21, 2014. | |